[Behavior of blood coagulation factors under the effect of a new pyrazol derivative during prolonged anticoagulant therapy].
D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis*; D001780:Blood Coagulation Tests; D003327:Coronary Disease / Q000188:drug therapy*; D003374:Coumarins / Q000627:therapeutic use*; D003864:Depression, Chemical; D001728:Dicumarol / Q000627:therapeutic use*; D005165:Factor V / Q000032:analysis; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005260:Female; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012702:Serotonin Antagonists; D013268:Stimulation, Chemical; D013924:Thrombophlebitis / Q000188:drug therapy*; D013997:Time Factors
D000700:Analgesics; D001779:Blood Coagulation Factors; D003374:Coumarins; D012702:Serotonin Antagonists; D001728:Dicumarol; D005165:Factor V; D005167:Factor VII; D005170:Factor X
Das Verhalten der Blutgerinnungsfaktoren unter der Wirkung eines neuen Pyrazol-Derivates bei Langzeitbehandlung mit Anticoagulantien.